Somatotropin Deficiency Pipeline, Clinical Trials Studies, Emerging Drugs and FDA Approvals 2023 (Updated)

DelveInsight's, "Somatotropin Deficiency Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Somatotropin Deficiency pipeline landscape. It covers the Somatotropin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Somatotropin Deficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Somatotropin Deficiency Pipeline Report
• DelveInsight's Somatotropin Deficiency pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Somatotropin Deficiency treatment.
• The leading companies working in the Somatotropin Deficiency Market include I-MAB Biopharma Co., Ltd., Lumos Pharma, Xiamen Amoytop Biotech Co., Ltd., and others.
• Promising Somatotropin Deficiency Pipeline Therapies in the various stages of development include ARX201, Macimorelin, Y-shape pegylated somatropin, Norditropin®, Macimorelin, and others.
• September 2023: I-Mab Biopharma Co. Ltd announced a study of phase 3 clinical trials for TJ101 and NordiFlex. A Phase III, Randomized, open-label, positive-drug parallel control, Study to Evaluate the Efficacy and Safety of TJ101 in Child subject with growth hormone deficieney.
• October 2023: Lumos Pharma announced a study of phase 2 clinical trials for LUM-201 and rhGH Norditropin® pen (34 µg/kg). This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.

Request a sample and discover the recent advances in Somatotropin Deficiency Treatment Drugs @ Somatotropin Deficiency Pipeline Report- https://www.delveinsight.com/report-store/somatotropin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Somatotropin Deficiency pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Somatotropin Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Somatotropin Deficiency Overview
Somatotropin also known as growth hormone is about 190 amino acid long and is synthesized and secreted by somatotroph cells present in anterior pituitary. Somatotropin plays a major role in certain complex physiological processes such as growth and metabolism. Inadequate secretion of somatotropin hormone can lead to growth hormone deficiency or Somatotropin Deficiency in humans. The disease can either be present from birth (congenital) due to genetic mutations or from structural defects in brain or else can be acquired in later stage of life owing to tumors in pituitary, radiations, central nervous system infections, or severe head injuries.

Find out more about Somatotropin Deficiency Therapeutics Assessment @ Somatotropin Deficiency Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/somatotropin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Somatotropin Deficiency Emerging Drugs Profile
• TJ101: I-MAB Biopharma Co., Ltd.
Eftansomatropin alfa (TJ101) is a potential highly differentiated long-acting recombinant human growth hormone being developed as a more convenient and effective therapy for growth hormone deficiency (GHD). Like endogenous growth hormone, eftansomatropin alfa stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth. IGF-1 is a reliable pharmacodynamic marker and the key mediator of growth-promoting activity of eftansomatropin alfa.

Somatotropin Deficiency Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the Somatotropin deficiency therapies. The Somatotropin deficiency companies which have their Somatotropin deficiency drug candidates in the most advanced stage, i.e. phase III include, I-MAB Biopharma.

Somatotropin Deficiency Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Somatotropin Deficiency Pipeline Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Somatotropin Deficiency Pipeline Assessment
• Inactive drugs assessment
• Somatotropin Deficiency Unmet Needs

Learn more about the emerging Somatotropin Deficiency Pipeline Therapies @ Somatotropin Deficiency Clinical Trials Assessment- https://www.delveinsight.com/sample-request/somatotropin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Somatotropin Deficiency Pipeline Report
• Coverage- Global
• Somatotropin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Somatotropin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Somatotropin Deficiency Companies- I-MAB Biopharma Co., Ltd., Lumos Pharma, Xiamen Amoytop Biotech Co., Ltd., and others.
• Somatotropin Deficiency Pipeline Therapies- ARX201, Macimorelin, Y-shape pegylated somatropin, Norditropin®, Macimorelin, and others.

Dive deep into rich insights for new drugs for Somatotropin Deficiency Treatment, Visit @ Somatotropin Deficiency Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/somatotropin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Somatotropin deficiency: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Somatotropin deficiency- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. TJ101: I-MAB Biopharma Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Somatotropin deficiency Key Companies
21. Somatotropin deficiency Key Products
22. Somatotropin deficiency- Unmet Needs
23. Somatotropin deficiency- Market Drivers and Barriers
24. Somatotropin deficiency- Future Perspectives and Conclusion
25. Somatotropin deficiency Analyst Views
26. Somatotropin deficiency Key Companies
27. Appendix

For further information on the Somatotropin Deficiency Pipeline therapeutics, reach out to Somatotropin Deficiency Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/somatotropin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.